August 2, 2025, Rochester, MN – Emmyon is pleased to announce that it has received a new Phase II Small Business Innovation Research (SBIR) award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the U.S. National Institutes of Health (NIH). The funding will support development of novel therapeutics for obesity and type 2 diabetes. We are very grateful to the NIDDK and the NIH for their support of these efforts.
Home / News / Emmyon receives Phase II SBIR award from the National Institute of Diabetes and Digestive and Kidney Diseases